Stiolto Respimat is a drug owned by Boehringer Ingelheim Pharmaceuticals Inc. It is protected by 34 US drug patents filed from 2015 to 2017. Out of these, 12 drug patents are active and 22 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 16, 2030. Details of Stiolto Respimat's patents and their expiration are given in the table below.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Stiolto Respimat's patents.

Latest Legal Activities on Stiolto Respimat's Patents

Given below is the list of recent legal activities going on the following patents of Stiolto Respimat.

Event	Date	Patent/Publication
Today's Legal Activities
Payment of Maintenance Fee, 12th Year, Large Entity	19 Apr, 2023	US8044046
Payment of Maintenance Fee, 12th Year, Large Entity	03 Apr, 2023	US8034809
Payment of Maintenance Fee, 12th Year, Large Entity	23 Feb, 2022	US7786111
Payment of Maintenance Fee, 12th Year, Large Entity	24 Nov, 2021	US7727984
Payment of Maintenance Fee, 12th Year, Large Entity	11 Aug, 2020	US7491719
Patent Term Extension Certificate	16 Dec, 2019	US7727984
Payment of Maintenance Fee, 8th Year, Large Entity	16 Apr, 2019	US8044046
Payment of Maintenance Fee, 8th Year, Large Entity	02 Apr, 2019	US8034809
Notice of Final Determination -Eligible	02 Apr, 2019	US7727984
Payment of Maintenance Fee, 12th Year, Large Entity	14 Nov, 2018	US7220742

FDA has granted several exclusivities to Stiolto Respimat. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Stiolto Respimat, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Stiolto Respimat.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Download Report

Several oppositions have been filed on Stiolto Respimat's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Stiolto Respimat's generic, the next section provides detailed information on ongoing and past EP oppositions related to Stiolto Respimat patents.

Stiolto Respimat's oppositions filed in EPO

Stiolto Respimat has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 12, 2012, by Knorr-Bremse Systeme Für Nutzfahrzeuge Gmbh. This opposition was filed on patent number EP2004006768W. Click below to reveal the latest opposition data.

Application	Filing Date	Opposition Party	Legal Status
Live updates
EP05737938A	Apr, 2014	Aechter, Bernd	Opposition rejected
EP2004006768W	Apr, 2012	Knorr-Bremse Systeme für Nutzfahrzeuge GmbH	Revoked

US patents provide insights into the exclusivity only within the United States, but Stiolto Respimat is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Stiolto Respimat's family patents as well as insights into ongoing legal events on those patents.

Stiolto Respimat's family patents

Stiolto Respimat has patent protection in a total of 42 countries. It's US patent count contributes only to 10.3% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Stiolto Respimat.

Full family tree

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳

Generic Launch

About Stiolto Respimat

Stiolto Respimat is a drug owned by Boehringer Ingelheim Pharmaceuticals Inc. It is used for managing symptoms of chronic obstructive pulmonary disease (COPD) and treating respiratory complaints. Stiolto Respimat uses Olodaterol Hydrochloride; Tiotropium Bromide as an active ingredient. Stiolto Respimat was launched by Boehringer Ingelheim in 2015.